STOCKWATCH
·
Biotechnology: In Vitro & In Vivo Diagnostic Substances
SplitApr 17, 2026, 05:07 PM

VolitionRx Board Approves 1-for-20 Reverse Stock Split

AI Summary

VolitionRx Limited's Board of Directors has approved a one-for-twenty reverse stock split, following shareholder approval on March 31, 2026. The reverse stock split is expected to become effective at 12:01 a.m. ET on April 28, 2026, with shares trading on a split-adjusted basis at market open on the same day. This action is being taken in consideration of terms related to financing agreements with Lind Global Asset Management XII LLC.

Key Highlights

  • Board approved a one-for-twenty (1:20) reverse stock split.
  • Reverse stock split effective at 12:01 a.m. ET on April 28, 2026.
  • Shares to begin trading on a split-adjusted basis at market open on April 28, 2026.
  • Fractional shares will be rounded up to one whole share.
  • Action taken in consideration of financing terms with Lind Global Asset Management XII LLC.
VNRX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
VOLITIONRX LTD

Price Impact